Leerink Partners analyst Joseph Schwartz maintained a Hold rating on Amicus (NASDAQ:FOLD) Therapeutics on Monday, setting a price target of $13, which is approximately 26.83% above the present share price of $10.25.
Schwartz expects Amicus Therapeutics to post earnings per share (EPS) of -$0.27 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Amicus, with an average price target of $17.94.
The analysts price targets range from a high of $29 to a low of $12.5.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $70.57 million and a net profit of -$64.37 million. The company's market cap is $2.71 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.3% and a 50.45% success rate.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.